Solarea Bio, a Cambridge, MA-based clinical stage biotechnology company, raised $15M in Series B funding.
The round was led by S2G Ventures with participation from Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF. A total of up to $25M is targeted for this round of financing.
The company intends to use the funds for the commercial launch of two medical foods designed for the dietary management of bone health and rheumatoid arthritis, respectively.
Led by Gerardo V Toledo, CEO, Solarea Bio is a clinical stage biotechnology company mining the microbial diversity of fresh fruits and vegetables to develop novel solutions for managing inflammatory diseases and enabling people to enjoy healthy lives. It has built a strain catalog of bacteria and fungi, a database of their genomes, and a computational platform to mine them to develop products across a range of categories including supplements, medical foods, pharmaceuticals, and agriculture.
The first product, SBD111, a medical food designed to aid in the dietary management of bone loss in postmenopausal women demonstrated significant bone maintenance in a mouse model of postmenopausal osteoporosis and results were published in a peer-reviewed journal. The product demonstrated a safety and tolerability profile comparable to placebo in healthy subjects, and a large efficacy study is ongoing to demonstrate its effects on maintaining bone mass in postmenopausal women. The second medical food product, SBD121, is designed to aid in the dietary management of rheumatoid arthritis and will enter a human study this year.
FinSMEs
08/05/2023